Abstract. Primary hyperoxaluria type 1 (PH 1), an inborn error of glyoxylate metabolism characterized by excessive synthesis of oxalate and glycolate, is caused by a defect in serine:pyruvate/alanine:glyoxylate aminotransferase (SPT/AGT). This enzyme is peroxisomal in human liver. Recently, we cloned SPT/ AGT-cDNA from a PH 1 case, and demonstrated a point mutation of T to C in the coding region of the SPT/AGT gene encoding a Ser to Pro substitution at residue 205 (Nishiyama, K., T. Funai, R. Katafuchi, F. Hattori, K. Onoyama, and A. . Biochem. Biophys. Res. Commun. 176:1093-1099. In the liver of this patient, SPT/AGT was very low with respect to not only activity but also protein detectable on Western blot and immunoprecipitation analyses. Immunocytochemically detectable SPT/AGT labeling was also low, although it was detected predominantly in peroxisomes. On the other hand, the level of translatable SPT/AGT-mRNA was higher than normal, indicating that SPT/AGT had been synthesized in the patient's liver at least as effectively as in normal liver. Rapid degradation of the mutant SPT/AGT was then demonstrated in transfected COS cells and transformed Escherichia coli, accounting for the low level of immunodetectable mutant SPT/AGT in the patient's liver. The mutant SPT/AGT was also degraded much faster than normal in an in vitro system with a rabbit reticulocyte extract, and the degradation in vitro was ATP dependent. These results indicate that a single amino acid substitution in SPT/AGT found in the PHI case leads to a reduced half-life of this protein. It appears that the mutant SPT/AGT is recognized in cells as an abnormal protein to be eliminated by degradation.
S
:e RI N~:pyruvate/alanine :glyoxylate aminotransferase (EC 2.6.1.51/EC 2.6.1.44, SPT/AGT) ',2 is an enzyme whose organelle localization and hormone responsiveness differ with the animal species. In the liver of herbivorous animals, including man, this enzyme is peroxisomal, while in carnivores it is entirely or largely mitochondrial Takada and Noguchi, 1982; Danpure et al., 1990) . In rat liver, SPT/AGT is located in both peroxisomes and mitochondria, and only the mitochondrial enzyme is markedly induced by glucagon Oda et al., 1982) . It is well known that in eukary-otic cells each organelle participates in different cellular processes, and proteins involved in these processes are synthesized, predestined to be localized in a relevant subcellular compartment. Therefore, the peroxisomal and/or mitochondrial localization of SPT/AGT suggests that the enzyme in the different organeUes participates in different metabolic processes. With respect to the mechanism of directing SPT/ AGT to either one of the two organelles in rat liver, we recently demonstrated that transcription of a single SPT/AGT gene from different initiation sites in exon 1 eventually determines the alternative targeting of the expression product to either peroxisomes or mitochondria Yokota et al., 1991; Mori et al., 1992) .
Primary hyperoxaluria type 1 (PH 1), an inborn error of glyoxylate metabolism characterized by increased oxalate production, has been shown to be caused by a defect in SPT/AGT in peroxisomes in the liver (Danpure and Jennings, 1986) . This indicated that an important physiological role of peroxisomal SPT/AGT is to remove glyoxylate, preventing excessive production of oxalate, the injurious end product of metabolism. Glyoxylate is an immediate precursor of oxalate and is produced mainly in peroxisomes in the liver. Since SPT/AGT is the enzyme with the unique organelle targeting, phenotypes of cell biological interest are also observed in the deficiency of this enzyme in PH 1. Three phenotypic subgroups of PH 1 have been reported. The majority of PH 1 patients have nearly complete deficiencies of SPT/AGT catalytic activity and SPT/AGT immunoreactive protein, but approximately one-third belonging to the second phenotypic subgroup possess significant levels of residual SPT/AGT activity and immunoreactive protein (Wise et al., 1987; Danpure and Jennings, 1988; Danpure, 1991) . In the latter case, it has been reported that the disease appears to be due, at least in part, to a unique protein trafficking defect in which SPT/AGT is erroneously routed to the mitochondrion instead of its normal intracellular location, the peroxisome (Danpure et al., 1989) . Among patients with zero SPT/AGT activity, there is another subgroup which has immunoreactive SPT/AGT correctly located within the peroxisomes (Takada et al., 1990; Purdue et al., 1992) .
We recently studied a PH 1 case who had had recurrent urinary calculi since the age of 6, reached the end-stage renal failure at age 39, which necessitated hemodialysis, and died at age 46. We cloned SPT/AGT-cDNA from the PH 1 case, and demonstrated a point mutation of T to C at position 613 (relative to A of the initiation ATG codon) encoding a Ser to Pro substitution at residue 205. The T to C conversion created a new SmaI site, which enabled us to demonstrate that the mutation occurs in the patient's gene (Nishiyama et al., 1991) . In the liver of this patient, not only the SPT/AGT activity but also the protein detectable on Western blot and immunocytochemical analyses was low, but translatable SPT/AGT-mRNA was clearly detectable. In the present study, we demonstrated that the mutant SPT/AGT is unstable in cells and cell extracts, and decomposes much faster than normal. Although the biological and pathological importance of intracellular degradation systems to eliminate misfolded proteins has long been suspected, this is one of the still relatively few cases in which rapid degradation of mutant protein is demonstrated in a hereditary disease.
Materials and Methods

Liver Samples
Liver specimens obtained on autopsy 5-h postmortem from patients fiemale, 29 y, and male, 68 y) who died of other diseases and the PH 1 patient were immediately frozen in dry ice and stored at -80°C, as described previously (Nishiyama et al., 1991) .
RNA Blot Analysis
RNA blot analysis was performed according to Alwine et al. (1977) . Poly(A)-rich RNA was prepared from the PH 1 liver after extraction by the acid guanidinium thiocyanate-phenol-chloroform method (Chomczynski and Sacchi, 1987) . Control poly(A)-rich RNA was prepared from a liver specimen otained on autopsy approximately 5-h postmortem from a patient (29 y, female) who died of a malignant lymphoma. The denatured RNA (5 #g) was electrophoresed on a 1.2% agarose gel and then transferred to a nylon membrane (Hybond-N; Amersham International Pie, Buckinghamshire, England). A 32P-labeled 120-bp NcoI-HpaII fragment of human SPT/AGT cDNA (pHsptl2; Nishiyama et al., 1990 ) was used as a hybridization probe. 4 mo later, ~-actin mRNA on the same nylon membrane was determined as an internal standard using a 443-bp Hint-Hint fragment of human ~-actin genomic DNA (hHal60; Nakajima-Iijima et al., 1985) . Both DNA fragments were labeled by the random primer-labeling method (Feinberg and Vogelstein, 1983) with [tx-a2p] dCTP. Prehybridization and hybridization were performed at 55°C for 20 h in 5x NaCI/Pi/EDTA (Ix NaC1/Pi/EDTA: 0.18 M NaC1, 10 mM sodium phosphate [pH 7.4] , and 1 mM EDTA) containing 5× Denhardt's solution (Maniatis et al., 1982) , 0.5% (wt/vol) SDS, and 100 #g/ml denatured salmon sperm DNA. The membrane was washed twice with 5× NaCI/Pi/EI3q'A for 15 rain each at 55"C, twice in lx NaC1/Pi/EDTA containing 0.1% (wt/vol) SDS for 10 rain each at 55°C, and finally twice in 0.1X NaCI/Pi/EDTA containing 0.1% (wt/vol) SDS for 15 rain each at room temperature.
In Vitro Translation
RNA was synthesized in vitro from SPT/AGT eDNA clones isolated from control human liver (pHsptl2) (Nishiyama et al., 1990) or the patient's liver (pHOspt2) (Nishiyama et al., 1991) using T7 RNA polymerase (Melton et al., 1984) . Linealized template DNA (5 #g) was transcribed at 37°C for 5.5 h with 20 U of T7 RNA polymerase (New England Biolabs, Inc., Beverly, MA) in the presence of 10 mM DTT, 0.5 mM each of ATP, CTE and UTP, 0.05 mM GTE 0.5 mM PJ-5'-(7-methyl)-guanosine-p3-5 '-guanosine triphosphate (m:G[5~JPPP[5']G) (New England Biolabs, Inc.), and 40 U of human placental RNase inhibitor (Takara Shuzo Co., Ltd., Kyoto, Japan) in 40 mM Tris-HCl (pH 7.5) containing 6 mM MgC12, 2 mM spermidine, and 0.01% (wt/vol) BSA, in a final volume of 50 #1. RNA formed was extracted sequentially with phenol and chloroform, precipitated with ethanol, dried, and then dissolved in 20 #1 of diethyl pyrocarbonate-treated water.
Poly(A)-rich RNAs obtained from control liver and the patient's liver (1-t~g each) or RNA synthesized in vitro as above were translated in a reticulocyte lysate system in the presence of L-[aSS]methionine as described previously (Oda et al., 1981) . The translation products were immunoreacted with rabbit anti-rat mitochondrial SPT/AGT serum or rabbit nonimmune serum, and then precipitated by adsorption to Staphylosorb (Mercian Co., Tokyo, Japan). SDS/10% PAGE of the precipitates and fluorography were carried out as previously described (Oda et al., 1981) .
Construction of Human SPT/AGT Expression Plasmids
For expression in COS-1 cells, an EcoRI-EcoRI fragment of pHsptl2 or pHOspt2 (full-length SPT/AGT cDNAs containing EcoRI linkers at their 5' and 3' ends) was blunted with Klenow enzyme, and then directly introduced into a eukaryotic expression vector, pSVL, at the blunted Xhol site. The resultant recombinant plasmids were proliferated in Escherichia coli DH5~, and covalently closed circular plasmid DNAs were obtained by equilibrium centrifugation in cesium chloride-ethidium bromide gradients. They were designated as pSVLNOR for normal SPT/AGT and pSVLPH for the patient's SPT/AGT.
For expression in E. coli strain JMI05 cells, a prokaryotic expression vector, pKK233-2, was digested with HindliI, blunted with Klenow enzyme, and then cut with NcoI. An EcoRI-EcoRI fragment of pHsptl2 or pHOspt2 was blunted with Klenow enzyme and then cut at the Ncol site. The NcoI cleavage was carried out to shorten the 5:noncoding region of SPT/AGT eDNA to allow its efficient transcription in E. coll. After the Ncol cleavage, the ATG sequence in the NcoI site remained on the coding side of SPT/AGT-cDNA as the initiation ATG codon. The resultant SPT/AGT eDNA fragments were inserted into linealized pKK233-2 by ligation of both the NcoI cohesive terminal and the blunt-ended terminal. The constructed recombinant plasmids were designated as pKKNOR for normal SPT/AGT and pKKPH for the patient's SPT/AGT.
Expression of Human SPT/AGT in COS Cells and E. coli
COS-1 cells were transfected with pSVLNOR or pSVLPH by electroporation as described previously (Yokota et al., 1991) , except that 30 #g of the purified recombinant plasmids was cotransfected with 4 #g of pCHll0, a plasmid containing a functional lac Z gene which is expressed from the SV-40 early promoter, pCHll0 was used as an internal standard for monitoring the efficiency of the transient expression. The transfected cells were plated on 35-mm dishes and allowed to grow at 37°C for 48 h in DME supplemented with 10% (vol/vol) FCS, with a medium change at 12 h. The lysate of COS-1 cells was prepared as described previously (Yokota et al., 1991) , except that the lysis buffer comprised 50 mM Tris-HCl (pH 8.0), 150 mM NaC1, 1% (vol/vol) Triton X-100, 1 mM PMSF, 1/~g/ml aprotinin, and 0.02% (wt/vol) sodium azide.
E. coil JM105 was transform~l with pKKNOR or pKKPH according to Hanahan (1983) . 200 ml of M9CA medium (Maniatis et al., 1982) contain-ing 50 ~g/ml ampicillin, 10/zg/ml streptomycin, and 1 ~g/ml thiamine was inoculated with an overnight culture of E. coli JM105 transformed with one of the recombinant plasmids, followed by incubation at 37°C with shaking. When the absorbance at 600 tun reached 0.6, chlorampbenicol was added to a final concentration of 68/zg/ml, and then the incubation at 37°C was continued overnight. Cells were collected by centrifugation (5,000 g for 10 min at 4°C), washed with M9CA medium, and suspended in 50 ml of M9CA medium containing 50/~g/rrd ampicillin, 10/~g/ml streptomycin, and 1/~g/ml thiamine. After incubation for 1 h at 37°C, ceils were exposed to 1 mM isopropyi-l-thio-/~-l)-galactopyranoside for 18 h at 37°C to induce transcription from the trc promoter, and then immediately chilled in ice and harvested by centrifugation (5,000 g at 4°C for 10 rain). The pellet was washed with 0.5% (wt/vol) NaCI/0.5% (wt/vol) KCI, and then suspended in 40 ml of 50 mM potassium phosphate buffer (pH 7.2) containing 0.1 mM pyridoxal 5~phosphate, 1 mM pyruvate, 1 mM PMSF, and 10/~g/ml tmnsepoxy succinyl-L-leucylamido(3-methyl)botane (E-64C, a thiol protease inhibitor). The suspension was sonicated for 5 rain at 200 W using an Insonator (model 200 M; Kubota Manufacturing Co., Tokyo, Japan), and the lysate was clarified by centrifugation (14,800 g at 4°C for 10 rain). A portion of the E. coli suspension was centrifuged without sonication, and the pellet was dissolved in the SDS-gel loading buffer, immediately boiled for 5 rain, and subjected to SDS-PAGE.
Preparation of a Liver Extract
A control human liver and the patient's liver 0 g each) were homogenized with 5 vol of extraction buffer (50 mM Hepes [pH 7.4], 150 mM NaCI, 1 mM EDTA, 50 #M pyridoxai 5~phosphate, 0.02 % (wt/vol) sodium azide, and 1% (vol/vol) Triton X-100 containing 1 mM PMSE 1/zg/ml aprotinin, 1 ~g/ml antipain, 0.7 t~g/ml pepstatin A, 1 #g/ml leupeptin, and 10/~g/rnl E-64C) in a Potter-Elvehjem homogenizer in an ice bath. A sonicated extract was then prepared from each liver homogenate by sonication using an Insonator (model 200 M; 200 W for 15 rain in the cold), followed by centrifugation at 14,800 g for 10 rain at 4°C.
Western Blot Analysis
A polyclonal antibody against human SPT/AGT was raised in a white New Zealand rabbit (male) weighing 1.5 kg by subcutaneous injection of 0.1 mg of the purified enzyme in complete Freund's adjuvant by the method of Dunbar and Schwoebel (1990) . 3 wk and 6 wk later, the rabbit was again immunized with 0.05 mg of the antigen in incomplete Freund's adjuvant. Preimmune serum was obtained just before the first injection of the antigen. Antiserum was obtained 8 wk after the first injection.
Western blot analysis was performed with human liver sonicated extract (10/zg protein), COS-1 cell lysate (100/zg protein), E. coli JM105 sonicated extract (37.5/zg protein), or E. coli JM105 lysate from equivalent volume of cell suspension to that used for the preparation of sonicated extract, essentially according to Kruger and Hammond (1988) , using t25I-labeled protein A. Briefly, electrophoresis was carried out in an SDS/12% polyacrylamide gel, and then the gel was soaked in 25 mM Tris/192 mM glycine/15 % (vol/vol) methanol (pH 8.25) for 30 min, followed by electxophoretic transfer (2 mA/cm 2, for 2 h) to an Immobilon Transfer Membrane (Nihon Millipore Ltd., Tokyo, Japan). The membrane was incubated at room temperature for 1 h in a blocking buffer comprising 5% (wt/vol) nonfat dried milk and 0.05 % (vol/vol) Tween 20 in PBS, and then placed in diluted rabbit anti-human SPT/AGT serum (1:1,000) in the blocking buffer at 4°C for 16 h with gentle rotation. After washing five times for 10 rain each with PBS, the membrane was incubated at room temperature in 20 nil of PBS containing 4% (wt/vol) BSA and 37 kBq of 125I-labeled protein A for 2 h. After washing five times for 10 rain each with PBS containing 1% (vol/vol) Triton X-100, the membrane was dried and subjected to autoradiography using x-ray film and an intensifying screen.
Immunoprecipitation of Human SPT/AGT
Immunoprecipitation of human SPT/AGT was carried out using anti-human SPT/AGT serum and Staphylosorb or Pansorbin Cells (CalbiochemBehring Corp., Ida Jolla, CA) according to Sambrook et al. (1989) . Sonicared extracts from human livers and E. coli for 5 min), supernatants were incubated at 4°C for 2 h with anti-human SPT/AGT serum in NET-gel buffer, and then 10% (wt/vol) Staphylosorb or Pansorbin cells were added and the incubation was continued at 4°C for 1 h with gentle rocking. The amounts of anti-human SPT/AGT serum and Staphylosorb or Pansorbin cells used in each experiment are given in the legends to the figures. The immune complex adsorbed on Staphylosorb or Pansorbin cells was washed by vigorous vortexing for 2 rain each first with NET-gel buffer containing 0.5 M NaCl, then with NET-gel buffer containing 0.1% (wt/vol) SDS and finally with 10 mM Tris-HC1 (pH 7.5) containing 0.1% (vol/vol) NP-40. Denaturation of the proteins in the immunoprecipitate and analysis by SDS/12% PAGE were performed as described previously (Oda et al., 1981) . In a preliminary experiment in which [35S]methionine-labeled SPT/AGT in the COS-1 cell lysate (850 #g protein) was immunoprecipitnted using 50 #1 of 10% (wt/vol) Staphylosorb, essentially the same radioactivity was recovered in the 43-kD band (representing SPT/AGT) with any amount of anti-human SPT/AGT serum between 1 and 100 #1.
Pulse-Chase Experiment
Experiment with COS-1 Cells. COS-1 cells transfected with pSVLNOR or pSVLPH were cultured for 48 h as described above, and then washed twice with 2 ml of prewarmed (370C) methionine-free DME. The cells were further incubated for 20 rain at 37°C in 2 mi of methionine-free DME, followed by pulse-labeling with 740 or 1,110 kBq (20 or 30 pmol) of Expre3sS35S protein labeling mix (a mixture of [35S]methionine and [3SS]cysteine) for 20 min at 37°C in 0.5 ml of fresh methionine-free DME. The cells were then washed twice with prewarmed (37°C) DME supplemented with 10% (vol/vol) FCS, to which unlabeled L-methionine and L-cysteine were added to 225/~g/ml and 375 t~g/ml, respectively, and incubated at 37°C in 2 ml of the same medium for various periods of time. The incubated cells were washed with PBS, stored at -80°C, and lysates were prepared as described above.
Experiment with E. coil JMI05 Cells. E. coli JM105 cells bearing pKKNOR or pKKPH were cultured overnight in a small scale (2 ml of medium) as described above, and then washed twice with 1 ml each of M9CA medium supplemented with a mixture of all the L-amino acids (except methionine) at 20/~g/ml each, 50/zg/ml ampicillin, 10 #g/m1 streptomycin, and 1/~g/ml thiamine. The washed cells were suspended in 0.6 ml of the same medium and incubated for 10 rain at 37°C, and then isopropyl-1-thio-/~q)-galactopyranoside was added to 1 mM to induce the transcription of transfected pKKNOR and pKKPH. After incubation with shaking for 30 min at 37°C, 1.85 MBq (50 pmol) of L-[aSS]methionine was added and the incubation was continued for additional 5 rain. Unlabeled L-methionine was then added to 100 #g/ml, and 100-#1 aiiquots of the cell suspension were incubated in separate Eppendorf tubes (Brinkman Instruments Inc., Westhury, NY) for various periods of time with shaking at 37°C. The cells were harvested, washed with M9CA medium, resuspended in 100/~l of M9CA medium, and stored frozen in dry ice until all the samples were ready for sonication. The cell suspension was then sonicated in an Eppendoff tube three times for 10 s each at 8 W with the aid of an Ultrasonic Processor (model 7040; SEIKO Instruments & Electronics Ltd., Tokyo, Japan), and resultant sonicated extract was subjected to the reaction with anti-human SPT/AGT serum.
Degradation In Vitro with Rabbit Reticulocyte Extract
35S-labeled normal and mutant human SPT/AGT were synthesized from respective cDNAs in a "1"7 RNA polymerase-reticulocyte lysate system essentiaily as described above, with following changes, pAM19 containing EcoRI-EcoRI fragment of pHsptl2 or pHOspt2 was lineafized with BamHI, purified by treatment with 100/zg/ml proteinase K for 30 rain at 37°C in the presence of 0.5% SDS and used as template DNA. Spermidine was omitted from the transcription buffer, and after the transcription, the template DNA was digested with 300/~U/ml of RNase-free DNase I (Pharmacia, Uppsala, Sweden) for 15 min at 37°C. The concentration of synthesized RNA was determined spectrophotometrically by absorption at 260 nm, and the size of the RNA was checked by electrophoresis through agarose gel. A 0.2-/zg aliquot of the RNA formed was translated for 90 min at 25°C with 10/zl of rabbit reticulocyte lysate for in vitro translation, in the presence of 1.85 MBq of Expre35S3sS protein labeling mix in a methionine-free translation cocktail (Mori et al., 1979) , in a final vol of 25 /~1. The translation was stopped by adding 40/~g/ml of cycloheximide and 5 mM each of L-methionine and L-cysteine. The degradation of 35S-labeled SPT/AGT was then followed in a reaction mixture comprising 3 #1 of the translated SPT/AGT, 5 mM MgCl2, 5 mM ATE 1 raM DTT, and 30 td of rabbit reticulocyte extract for protein degradation in 50 mM Tris-HCl (pH 7.8), in a final volume of 60 #l. When energy requirement of the SPT/AGT degradation was to be examined, ATP was omitted from the reaction mixture, and 20 mM 2-deoxyglucose and 25 U/ml of hexokinase were added. After incubation at 37°C for various periods of time, a l(Y/~l aliquot of the reaction mixture was removed, mixed with 20/~l of SDS-gel loading buffer, and immediately boiled for 5 rain. One half of the sample was then subjected to SDS/10 % PAGE and autoradiography for estimation of the radioactivity in the 43-kD band.
Immunocytochemical Staining of Human SPT/AGT
Preparation of 1Issues. Frozen tissue blocks of biopsy and autopsy liver samples were put into ice-cold fixative I, that consisted of 4% (wt/vol) paraformaldehyde (Merck, Darmstadt, Germany), 0.2 % (vol/vol) glutaraldehyde (Nacalai Tesque Inc., Kyoto, Japan), 0.01% (wt/vol) CaC12, and 0.15 M cacodylate-HCl buffer (pH 7.4) (Yokota, 1990) , and then slowly thawed. The tissue blocks were embedded on the specimen folder of a Vibratome (Oxford Labs., City, CA) in agarose, cut into 200-/~m thick sections in a trough filled with fixative I, and then fixed for 2 h at 4°C. The sections were cut into about 1 mm x 1 nun cubes and divided into three groups. The first and second groups were fixed again in 2% (vol/vol) glutaraldehyde in 0.1 M cacodylate-HC1 (pH 7.4) buffer for 1 h at 4°C. The third group was further fixed in fixative I for an additional 1 h at 4"C. The first group was then postosmicated with 1% (wt/vol) reduced osmium tetroxide, dehydrated in a graded ethanol series, and then embedded in Epon (TAAB, London, England). The second group was stained for catalase by means of the alkaline diaminobermidine reaction (LeHir et al., 1979) , postosmicated, dehydrated, and then embedded in Epon. The third group was dehydrated in a graded dimethylformamide series and then embedded in LR White (Nippon Bio-Rad Laboratories, K. K., Tokyo, Japan) at -20°C. Polymerization of LR White was carried out under UV light at -20°C for 24 h (Yokota, 1990) , Ultra-thin sections were cut with an LKB Ultrotome (LKB, Broma, Sweden) equipped with a diamond knife. Thin sections of the first group were used for morphological observation. Diaminobenzidine staining of peroxisomal catalase was observed using thin sections of the second group.
Iramunoelectron Microscopic Procedures. Thin sections from the third group were mounted on uncoated nickel grids. Imrnunostaining procedures were based on the method of Roth (1982) . The sections were incubated in 1% (wt/vol) BSA for 5 rain. This was followed by overnight incubation with 50 #g proteirdml each of anti-human SPT/AGT serum, anti-rat mitochondrial SPT/AGT serum, anti-rat liver catalase serum or nonimmune serum at 4°C. After washing with PBS, the sections were incubated with a protein A-gold probe (15 nm in diameter) for 30 rain at room temperature. The sections were then washed with distilled water, air-dried, and contrasted with 2% (wt/vol) uranyl acetate for 3 rain and with 4% (wt/vol) lead citrate for 20 s. After carbon coating, the sections were examined under a Hitachi H600 electron microscope at an accelerating voltage of 75 kV. To evaluate the intracellular labeling density distribution, 10 micrographs of bepatocytes were taken. The surface areas of the paroxisomes, mitochondria, and cytoplasm in the positive pictures, enlarged to a final magnification of 40,000, were estimated with a semi-computing system, and then the number of gold particles on each area was determined (Yokota, 1986) . The labeling density was expressed as the number of gold particles per square micron (Bendayan et al., 1980) .
Other Methods
RNA was determined spectrophotometrically with the assumption that an absorbance reading of 1.0 at 260 nm corresponds to a concentration of 40 ~g/ml. The /3-galactosidase activity used to monitor the transfection efficiency was assayed using a TKO-100 Dedicated Mini Fluorometer (Hoefer Scientific Instruments, San Francisco, CA) essentially according to a technical bulletin for the/~-galactosidase assay by use of the fluorometer (contributed by W. A. Braell). The reaction mixture comprised 160 ttl of a reaction cocktail (25 mM Tris-HC1 [pH 7.5], 125 mM NaCl, 2 mM MgC12, 12 mM /~-mercaptoethanol, and 0.3 mM 4-methylumbelliferyl-#-o-galactoside) and 40 #1 of COS-1 cell lysate (20 #g protein). The reaction was carried out at 37"C for 30 min and was stopped by adding 50 #1 of 25 % (vol/vol) TCA, followed by cooling on ice. The samples were centrifuged for 2 rain at room temperature in an Eppendorf microfuge. The resulting supernatant (100 t~l) was added to 2 ml of glycine-earbonate roagent (133 mM glycine and 83 mM Na2CO3 IpH 10.7]), and then the fluorescence (excitation at 380 nm, emission at 460 nm) was read with a TKO-100 Mini Fluorometer (Hoefer Scientific Instruments). 1 U of the /~-galactosidase activity was expressed arbitrarily as the activity that produced 1 pmol of 4-methylumbelliferone in 30 rain at 37"C. Under these conditions the B-galaetosidase activity determined in COS-1 cells transfected with pSVLNOR or pSVLPH was '~50 U per 20 #g protein of cell lysate. The B-galaetosidase activity obtained in COS-1 cells into which pSVLNOR or pSVLPH was cotransfected with pCltll0 ranged from 400 to 1,200 U per 20 ttg protein of ceU lysate, but the variation in the enzyme activity at each time point in one pulse-chase experiment was within 20% of the average. The protein concentrations in extracts from human livers, COS-1 cells and E. coli JMI05 calls were measured by the Bradford method .
Materials
E-64C, a thiol protease inhibitor, was kindly donated by Research Laboratories, Taisho Pharmaceutical Co., Ltd. (Saitama, Japan). COS-1 cells were provided by the Japanese Cancer Research Resources Bank (Tokyo, Japan). Male New Zealand white rabbits were purchased from Japan SLC, Inc. (Hamamatsu, Shizuoka, Japan), and a nuclease-treated rabbit reticulocyte lysate for in vitro translation was prepared as described by Pelham and Jackson (1976) , A rabbit reticulocyte extract for in vitro protein degradation was prepared according to Fagan et al. (1986) . A reticulocyte extract used in preliminary experiments for in vitro protein degradation was kindly donated by Drs. K. l~anaka and A. Ichihara (Institute for Enzyme Research, University of Tokushima, Japan). 
Results
RNA Blot Analysis
On RNA blot analysis with poly(A)-rich RNA, a single band of SPT/AGT mRNA was observed in both control and patient liver. The size of the patient's SPT/AGT mRNA was the same as that of the 1.7-kb SPT/AGT mRNA from control human liver. On densitometric analysis, the level of SPT/AGT mRNA in the patient's liver (Fig. 1, lane 1) was found to be approximately three times higher than that in control human liver (Fig. 1, lane 2) . On the other hand, the level of 2.0-kb human ~-actin mRNA used as an internal standard was almost the same among control and patient liver poly(A)-rich RNAs (Fig. 1, lanes 3 and 4) .
In Vitro Translation
In vitro translation was carried out in a rabbit reticulocyte lysate system, and the products were analyzed by SDS/PAGE after immunoprecipitation with anti-rat mitochondrial SPT/ AGT serum or non-immune serum. As shown in Fig. 2 , an immunoprecipitated band of approximately 43 kD was observed as the translation product from both the control human liver (Fig. 2, lane 3) and patient liver (Fig. 2, lane 5 poly(A)-rich RNAs. The immunological cross-reactivity of the translation product for human SPT/AGT with the anti-rat mitochondrial SPT/AGT antibody had been demonstrated previously (Nishiyama et al., 1990) , and the patient's liver SPT/AGT was also shown to react with the anti-rat mitochondrial SPT/AGT antibody in this study. The amount of the 43-kD product translated from the patient's liver poly(A)-rich RNA was even higher than that from the control.
Cell-free translation was also carried out with RNA synthesized in vitro from the T7 RNA polymerase promoter in SPT/AGT cDNA clones isolated from control human liver (pHsptl2) and the patient's liver (pHOspt2). The translation products from the synthesized RNAs reacted with the anti-rat mitochondrial SPT/AGT antibody (Fig. 2 , lanes 7 and 9) and have the same molecular mass as that of the in vitro translation product from liver poly(A)-rich RNA. We previously showed that the isolated clones, pHsptl2 and pHOspt2, have a cDNA insert which encompasses the whole coding region of human SPT/AGT mRNA, and this coding region encodes a protein of approximately 43 kD (Nishiyama et al., 1990 (Nishiyama et al., , 1991 . Therefore, the results of the in vitro translation suggest that the same translation initiation ATG codon defines an open reading frame of 392 codons in both normal and patient SPT/AGT mRNA. In addition, RNA synthesized from pHOspt2 directed the in vitro translation at least as effectively as RNA synthesized from pHsptl2, as judged from the time course of translation and the effect of the amount of RNA used (data not shown). These results together suggested that the patient's SPT/AGT-mRNA was translatable. This suggestion was also supported by the results from pulse labeling in COS cells and E. coli described below. It was thus indicated that SPT/AGT had been synthesized in the patient's liver at least as effectively as in the control liver.
Western Blot Analysis and Immunoprecipitation of Human SPT/AGT
Despite the suggestion that the mutant SPT/AGT had been synthesized in the patient's liver, Western blot analysis carfled out with not only the anti-rat mitochondrial SPT/AGT antibody but also the anti-human SPT/AGT antibody failed to detect the mutant SPT/AGT, when 10/~g protein of extract from the patient's liver was subjected to analysis (Fig. 3, lane  3) . The mutant SPT/AGT was detectable when as much as 500/~g protein of the liver extract was subjected to Western blot anlysis (Fig. 3, lane 9) . In contrast, a single band of 43 kD was clearly observed for the control human liver (Fig.  3 , lane 2) when 10 ftg protein of liver extract was applied. When 500/zg protein of the control liver extract was applied, Figure 3 . Western blot analysis. The experimental procedures were as described under Materials and Methods, except that 500/~g protein of liver extracts was subjected to the analysis where indicated. Blots were probed with a rabbit antibody raised against normal human SPT/AGT. Signals were developed using t25I-labeled protein A from Staphylococcus aureus. 20 ng protein of purified human SPT/AGT (lane 1 ), 10/~g protein of a sonicated liver extract from a 29-yr-old control subject (lane 2) and the PH 1 patient (lane 3), 100 tzg protein of a COS 1 cell lysate transfected with pSVLNOR (lane 4) and pSVLPH (lane 5), and 37.5 #g protein of a sonicated extract of E. coli JM105 ceils transformed with pKKNOR (lane 6) and pKKPH (lane 7) were analyzed by SDS/12% PAGE. In lanes 8 and 9, 500/~g protein of the liver extracts from the control and the PH 1 patient was applied, respectively. The Western blot analyzes of 10 #g (lanes 2 and 3) and 500 #g (lanes 8 and 9) liver extracts were carried out in separate experiments. The molecular size the 43-kD band of normal human SPT/AGT became gigantic (Fig. 3, lane 8) . The bands corresponding to normal and patient SPT/AGT (Fig. 3, lanes 8 and 9) were cut out and the radioactivity was measured. The radioactivity of the normal SPT/AGT band was 35 times higher than that of the patient's SPT/AGT.
In another experiment, COS-1 cells transfected with pSVLNOR or pSVLPH were cultured for 48 h and then pulse labeled with [3sS]methionine/cysteine for 20 rain. A cell lysate was then prepared and subjected to Western blot analysis. The COS-1 ceils transfected with pSVLPH synthesized the immunoprecipitable 43-kD protein (SPT/AGT) as effectively as the cells transfected with pSVLNOR, as judged on pulse labeling with [35S]methionine/cysteine, but no discernible amount of the mutant SPT/AGT was accumulated in the cells, while normal SPT/AGT was distinctly detectable (Fig. 3, lanes 4 and 5) . Likewise, no accumulation of the mutant SPT/AGT was observed in E. coli JM105 cells bearing pKKPH (Fig. 3, lanes 6 and 7) . Transformed E. coli ER1458, a Ion-strain, also failed to accumulate discernible amount of the mutant SPT/AGT, as judged by immunoperoxidase method (data not shown). Misfolded proteins often form insoluble aggregates, especially when overproduced in prokaryotic ceils, but in experiments with E. coli both normal and mutant SPT/AGTs were expressed only to a level which was detectable by Western blot analysis. In addition, when transformed E. coli (JM105 and ER1458) was dissolved in SDS-gel loading buffer without sonlcation and subjected to Western blot analysis without centrifugation, the same results as those with sonlcated supernatants (Fig. 3 , lanes 6 and 7) were obtained. In experiments with COS-1 cells, no aggregates of the mutant SPT/AGT were detectable immunocytochemically. These results suggested, although not proved, that the failure in detecting the immunoreactive mutant SPT/AGT was not entirely due to failure to extract the enzyme.
We also tried to recover the mutant SPT/AGT from a sonic extract of the patient's liver by reaction with the anti-human SPT/AGT antibody in solution. SPT/AGT was immunopre- cipitated from a sonic extract of the control liver and recovered as the 43 kD product (Fig. 4, lane 3) , but no specific band of 43 kD was detected when the sonic extract of the patient's liver was subjected to immunoprecipitation (Fig. 4 , lane 5). These findings indicated that the patient's liver contained an extremely low level of the mutant SPT/AGT, probably due to rapid degradation.
Immunocytochemical Staining of SPT/AGT in Control and Patient Liver
The intracellular localization of mutant SPT/AGT in the patient's liver was studied immunocytochemically using anti-human SPT/AGT serum and anti-rat mitochondrial SPT/AGT serum. Fig. 5 shows the results obtained with anti-human SPT/AGT serum. Quantitative analysis of the labeling density was carried out in a separate experiment involving anti-rat mitochondrial SPT/AGT serum.
In a fresh liver preparation, gold particles showing catalase were present exclusively in peroxisomes. Other cell organelles such as mitochondria and ER were consistently almost negative for catalase. The labeling densities (gold particles//~m 2) in mitochondria and the cytoplasmic matrix were calculated to be 0.39% and 0.48% of that in peroxisomes, respectively (Table I) . When sections from the same preparation were incubated with either anti-rat mitochondrial SPT/AGT serum or anti-human SPT/AGT serum, heavy labeling with gold particles was observed almost exclusively in peroxisomes. Few gold particles were present in mitochondria and the cytoplasmic matrix (Fig. 5 a, and Table I ).
In postmortem preparations of liver, preservation of the hepatocyte ultrastructure was considerably poor, most mitochondria being markedly swollen and having lost their cristae. Some mitochondria contained electron-dense material (Fig. 5, c-f ). Most peroxisomes showed partial membrane disruption. The intact region of the membrane was associated with the endoplasmic reticulum membrane (Fig. 5, c-e). The peroxisomal matrix aggregated to form a flocculent configuration which was never observed in the peroxisomes of a fresh liver preparation. Nevertheless, gold particles showing the antigenic sites for catalase were almost confined to peroxisomes in autopsy liver preparations from patients who died of other diseases (Table I) . Gold particles Labeling densities (gold particles//~m 2) are expressed as percentages of the density in peroxisomes of each liver sample. Values are the mean of 10 determinations on different electron micrographs of hepatocytes in the same liver specimen. Experimental procedures are described under Materials and Methods. showing the SPT/AGT antigens sites were also detected mainly in peroxisomes, but a few particles were scattered outside the peroxisomes (Fig. 5 c) . The labeling densities of SPT/AGT in mitochondria and the cytoplasmic matrix were 15.0 and 8.5 % of that in peroxisomes, respectively (Table I ). In the liver of the PH 1 patient, in which gold labels for catalase were concentrated in the peroxisomes (Table I) , gold particles showing SPT/AGT antigenic sites were scarce on the whole but were detected mainly in peroxisomes (Fig. 5  e) . The labeling density relative to that in peroxisomes were approximately 25.6% in mitochondria and 14.4% in the cytoplasmic matrix. The mitochondrial labeling density was higher than the cytoplasmic background, but the ratio of the labeling density in mitochondria to that in the cytoplasmic matrix was about the same in the control autopsy sample and the PH 1 sample. No gold particles were noted in any of the control sections in which non-immune serum was used instead of anti-SPT/AGT serum (Fig. 5, b, d, and f ) . The immunocytochemical analysis suggested that the mutant SPT/ AGT had been synthesized in the patient's liver, predestined to be localized in peroxisomes. It also appeared from the experiment that SPT/AGT leaks from peroxisomes more readily than catalase during the postmortem cell destruction (c.f. Table I ). Several peroxisomal matrix enzymes have been shown to vary in how easily they leak out when isolated rat liver peroxisomes are subjected to mechanical damages (Alexon et al., 1985) .
Degradation Rate of Normal and Patient SPT/AGT
The degradation rate of 35S-labeled SPT/AGT was analyzed in an attempt to reveal whether or not the low content of immunoreactive SPT/AGT in this PH 1 patient is due to instability of the mutant SPT/AGT in the cells. The COS-1 ceils and E. coli JM105 used in this experiment did not produce SPT/AGT by themselves. In this experiment, pSVLNOR or pSVLPH was cotransfected into the COS-1 cells with pCHll0, a plasmid coding for ~-galactosidase activity, to monitor the efficiency of the transient expression. The/~-galactosidase activity in cell lysate was almost the same between the COS-1 cells transfected with pSVLNOR and pSVLPH, indicating that pSVLNOR and pSVLPH were almost equally transfected. As shown in Fig. 6 , the pulse-chase experiments with COS-1 cells demonstrated that normal SPT/AGT is relatively stable and is degraded with an apparent half-life of approximately 11 h. However, the protein concentration in COS-1 cell lysate increased with time, and after 24 h, it reached a 1.5 to 1.9 times higher level than that at time zero. It thus appears that the pulse-labeled SPT/AGT was diluted by the growth and multiplication of COS-1 cells with time and the half-life of normal SPT/AGT was underestimated. On the other hand, the decay of the patient's SPT/AGT in COS-1 cells was distinctly rapid. Approximately 90% of the labeled SPT/AGT was lost within 6 h, with an apparent halflife of approximately 1.8 h, and after 24 h, the labeled 43-kD band was no longer detectable. During the degradation of the patient's SPT/AGT, no immunoprecipitable products with higher molecular masses, such as the conjugates with other proteins, were detectable on SDS-PAGE analysis, but a minor band with a smaller molecular mass (37 kD) was observed throughout the incubation period, in addition to the major band (43 kD) of normal and patient SPT/AGTs (Fig.  6 a, arrowhead) . The 37-kD protein appeared to be derived through translation from a downstream AUG codon rather than a degradation product of the 43-kD SPT/AGT.
The pulse-chase experiment with transformed E. coli also demonstrated the rapid decay of the mutant SPT/AGT. As shown in Fig. 7 , an almost equal amount of immunoprecipitable SPT/AGT was synthesized during 5-min pulse labeling with [35S]methionine in both E. coli JM105 cells bearing pKKNOR and pKKPH. Thereafter, normal SPT/ AGT was stable and rather increased about 2.5-fold in the course of chase incubation for unknown reasons. On the other hand, pulse-labeled patient's SPT/AGT was rapidly degraded, with an almost 60% decrease during the first 1 h. Tanaka et al. (1983) demonstrated that two distinct nonlysosomal ATP-dependent proteolytic systems exist in reticulocytes; one requires ubiquitin and the other is independent of ubiquitin. We then examined degradation of the patient's SPT/AGT in a rabbit reticulocyte extract system with special attention to the ATP-dependency (Fig. 8). [3~S]labeled nor- mal and mutant human SPT/AGTs synthesized from respective cDNAs were incubated with rabbit reticulocyte extract for protein degradation in the presence of ATP or under conditions of ATP depletion established by adding 2-deoxyglucose and hexokinase instead of ATP. Normal human SPT/ AGT was stable and almost all the 3~S-labeled enzyme was retained after 120-min incubation in either the presence or the absence of ATP. In contrast, the patient's SPT/AGT decreased to a very low level after 90-120-min incubation for degradation in the presence of ATP, and the degradation was distinctly dependent on ATP.
Discussion
This study is the first to provide information as to the molecular mechanism responsible for the SPT/AGT deficiency in primary hyperoxaluria type I due to rapid degradation of mutant SPT/AGT. The PH 1 patient presented had decreased SPT activity (~1% of the normal level) and his SPT/AGT gene had a homozygous point mutation in the coding region, as demonstrated previously (Nishiyama et al., 1991) . In an attempt to purify the mutant SPT/AGT from the patient's liver by the same procedures as those described previously for normal human SPT/AGT (Nishiyama et al., 1990) , protein(s) with the low SPT activity behaved in both phosphocellulose and hydroxylapatite column chromatographics quite differently from normal SPT/AGT. In addition, no band with a molecular mass of 43 kD was detected in fractions with the SPT activity on SDS/PAGE analysis (data not shown). Since some other aminotransfcrascs are known to exhibit weak SPT activity, it is highly possible that the low SPT activity detected in the patient's liver is not entirely that of the mutant SPT/AGT. Western blot analysis performed in this study demonstrated that not only the activity (<1% of normal) (Nishiyama et al., 1991) but also the immunoreactivc protein (*2.8 % of normal) was severely decreased (c. f. Fig. 3 ). RNA blot analysis and in vitro translation of mRNA from the patient's liver indicated that the enzyme deficiency is duc to neither a defect in transcription of the SPT/AGT gene nor one in the translation of the message. Estimation of the decay rate of SPT/AGT in COS-I cells and E. coli JMI05 revealed that the patient's SPT/AGT was unstable in the cells and rapidly degraded as compared with normal SPT/AGT. In COS-I cells, the half-life of the paticnfs SPT/AGT was about 6 times shorter than that of normal SPT/AGT (c.f. Fig. 6 b) . The patient's SPT/AGT was also degraded rapidly in vitro in rabbit reticulocyte extract in an ATP-dependent manner. From these results, we suspect that the enzyme defect in this patient is accounted for, at least in part, by the instability and intracellular rapid degradation of the mutant SPT/AGT. This is likely to be due to a point mutation in the patient's SPT/AGT gcnc leading to a substitution of Scr to Pro at residue 205 of SPT/AGT. Nonlysosomal, energy-and ubiquitin-dcpendent processes arc supposed to be involved in selective removal of unnecessary proteins with a rapid turnover, such as cyclin (Glotzcr ct al., 1991) and c-Mos (Nishizawa ct al., 1992) which arc closely related to cell cycle progression, and of abnormal proteins generated in cells (Rechsteiner, 1991) . In these processes, ubiquitin serves as a signal for degradation of proteins, and a novel ATP-dcpendent protease complex with an apparent sedimentation cocIiicient of 26S (26S proteasomc) appears to bc responsible for recognition of ubiquitinated proteins and their subsequent ATP-dependcnt degradation (Matthews et al., 1989; Goldberg, 1992) . In this study, the degradation of the mutant SPT/AGT in reticulocyte extract was clearly ATP dependent. However, no immunoreactive products with higher molecular masses, such as the conjugates with ubiquitin, wcrc detectable during the course of its degradation in either the transfected COS ceils or the in vitro reticulocyte lysate system, under the conditions used. Although ubiquitin-dependency of degradation of the mutant SPT/AGT in eukaryotic cells has to be further examined before conclusion, it is worthwhile to notice that ornithine decarboxylase was recently found to be degraded ATP and antizyme dependently by the 26S proteasome without ubiquitination (Murakami et al., 1992) . The observation that the patient's SPT/AGT was also degraded in E. coli would be of great interest, if it means that the mutant enzyme is recognized as an abnormal protein to be degraded in the two phylogenetically distant cells. However, since we have not yet studied in detail the degradation in E. coli, we would like to reserve any discussion on the bacterial degradation before elucidation of the underlying mechanism.
With respect to the degradation of the mutant SPT/AGT in vitro, no degradation occurred in reticulocyte lysate for translation, probably because, at least in part, the lysate contained 40/~M heroin. In reticulocyte lysate, heroin appears to promote protein synthesis by preventing the inactivation of a specific factor (eif-2) through the mediation of a hemedependent kinase (Datta et , 1983) . In the present study, the hemin concentration in the reaction mixture for degradation of 3sS-labeled SPT/AGT was lowered to 0.8/zM by minimizing the carry-over from the in vitro translation mixture.
It is known that peroxisomal proteins are synthesized on free polysomes, released into the cytosol, and then transported into peroxisomes . On the other hand, functional proteolytic systems such as the ATPdependent 26S proteasome have been found in the cytosol , but proteolytic systems in peroxisomes have not been clearly demonstrated. In the case of the PH 1 patient, immunocytochemically detected SPT/AGT antigenic sites were scarce on the whole but were concentrated predominantly in peroxisomes, suggesting that mutant SPT/ AGT retained the capacity of targeting the proper organelle. However, it still remains to be clarified where the mutant enzyme is degraded rapidly, i.e., in the cytosol during the transport to peroxisomes or in the peroxisomes after transport. Preliminary results obtained to date demonstrated the mutant SPT/AGT degradation in the cytosol of transfected COS cells, although they have not yet excluded a possibility that the mutant protein is also degraded in peroxisomes. If the degradation occurs only or mainly in the cytosol, then it should be answered whether the mutant enzyme is degraded during the normal transport into peroxisomes or is degraded rapidly partly because the enzyme stays longer in the cytosol due to impaired or inefficient transport. Kinetic studies on transport into peroxisomes of the mutant SPT/ AGT in comparison with the kinetics of its degradation will give us an answer, but for this purpose characterization of the proteolytic system(s) responsible for the degradation of the mutant SPT/AGT is indispensable as a prerequisite.
Another major question still remains to be answered is whether or not the mutant SPT/AGT has enzyme activity and what kind of conformational change is caused by the Ser to Pro substitution at residue 205. We have been especially anxious for the purification of the mutant enzyme, but since E. coli transformed with the recombinant plasmid, pKKPH did not accumulate the mutant SPT/AGT, we have not been successful at the purification. Continued trials to purify the mutant SPT/AGT are under way.
